Ayala Pharmaceuticals Inc (ADXS)

[DewDiligence]

The ADXS-NEO trial uses “3+3” dose escalation (scan down to the flowchart in http://onbiostatistics.blogspot.com/2015/01/phase-i-dose-escalation-study-design-3.html ), so it’s doubtful that the optimal dose had even been reached when AMGN made its decision to bail on the program.

Corollary: It seems unlikely that a lack of tumor response was the main impetus for AMGN’s decision.